Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06455904
Other study ID # 2023-005
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 30, 2024
Est. completion date January 13, 2027

Study information

Verified date June 2024
Source Institut de cancérologie Strasbourg Europe
Contact Joris MALLARD, PhD
Phone 368767419
Email j.mallard@icans.eu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The association of anthracyclines (ANT) and paclitaxel (Tax) is one of the main treatments used in breast cancer. These treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. If exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. Among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. The PROTECT-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. The duration of the training program is 15 weeks with one session per week.


Description:

There will be two groups of patients after drawing lots using a process called randomization. The probability is one in two of being in the group participating in the training program, the other group following the standard treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 156
Est. completion date January 13, 2027
Est. primary completion date January 13, 2027
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Woman = 18 years old - Stage I to III breast cancer - Patient currently planning (neo)adjuvant treatment combining anthracycline-cyclophosphamide and weekly paclitaxel (± trastuzumab) - Affiliation to a social security system - Able to speak, read and understand French Exclusion Criteria: - No prior chemotherapy treatment - Any known cardiac or vascular pathology - Contraindications to physical fitness assessment - Protected adult - Psychiatric, musculoskeletal or neurological problems - Pregnant or breastfeeding woman (NB: this population is already subject to a contraindication to (neo)adjuvant treatment. For women of childbearing age, a betaHCG dosage is already carried out systematically before the start of chemotherapy and information on the need for contraception throughout the chemotherapy period is provided before the start of treatment. As part of this study, only the presence of this test with a negative result at the start of chemotherapy will be checked. inclusion, if available).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Training sessions
The training program will be performed during 15 weeks, with one session per week.

Locations

Country Name City State
France Hôpitaux civils de Colmar Colmar
France Institut de cancérologie Strasbourg Europe Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
Institut de cancérologie Strasbourg Europe

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall exercise capacity To investigate the superiority of a concentric pedaling training program during (neo)adjuvant chemotherapy versus the absence of a training program in patients with early breast cancer. The overall exercise capacity is assessed by the 6-minute walk test (TDM6) between the two groups. At week 18 (the end of chemotherapy treatment)
Secondary Physiological variables associated with exercise capacity - cardiorespiratory capacity To examine the effects of the training program on VO2max. At weeks 8.
Secondary Physiological variables associated with exercise capacity - cardiorespiratory capacity To examine the effects of the training program on VO2max. At week 18 (the end of chemotherapy treatment)
Secondary Physiological variables associated with exercise capacity - muscle function To examine the effects of the training program on maximal aerobic power determined as the lowest exercise intensity inducing a plateauing of O2 consumption during a maximum exercise test. At weeks 8.
Secondary Physiological variables associated with exercise capacity - muscle function To examine the effects of the training program on maximal aerobic power determined as the lowest exercise intensity inducing a plateauing of O2 consumption during a maximum exercise test. At week 18 (the end of chemotherapy treatment)
Secondary Physiological variables associated with exercise capacity - body composition To examine the effects of the training program on lean mass, fat mass, muscle mass assessed by bioimpedancemetry. At weeks 8.
Secondary Physiological variables associated with exercise capacity - body composition To examine the effects of the training program on lean mass, fat mass, muscle mass assessed by bioimpedancemetry. At week 18 (the end of chemotherapy treatment)
Secondary Physiological variables associated with exercise capacity - muscle architecture To examine the effects of the training program on muscle thickness assessed by ultrasonography. At weeks 8.
Secondary Physiological variables associated with exercise capacity - muscle architecture To examine the effects of the training program on fascicle length assessed by ultrasonography. At weeks 8.
Secondary Physiological variables associated with exercise capacity - muscle architecture To examine the effects of the training program on cross-sectional area assessed by ultrasonography. At weeks 8.
Secondary Physiological variables associated with exercise capacity - muscle architecture To examine the effects of the training program on muscle thickness assessed by ultrasonography. At week 18 (the end of chemotherapy treatment)
Secondary Physiological variables associated with exercise capacity - muscle architecture To examine the effects of the training program on fascicle length assessed by ultrasonography. At week 18 (the end of chemotherapy treatment)
Secondary Physiological variables associated with exercise capacity - muscle architecture To examine the effects of the training program on cross-sectional area assessed by ultrasonography. At week 18 (the end of chemotherapy treatment)
Secondary Psychosocial variables associated with exercise capacity - quality of life To examine the effects of the training program with the FACT-G questionnaire At weeks 8.
Secondary Psychosocial variables associated with exercise capacity - quality of life To examine the effects of the training program with the FACT-G questionnaire At week 18 (the end of chemotherapy treatment)
Secondary Psychosocial variables associated with exercise capacity - fatigue To examine the effects of the training program with the FACIT-F questionnaire At weeks 8.
Secondary Psychosocial variables associated with exercise capacity - fatigue To examine the effects of the training program with the FACIT-F questionnaire At week 18 (the end of chemotherapy treatment)
Secondary Psychosocial variables associated with exercise capacity - appetite level To examine the effects of the training program with the FAACT questionnaire At weeks 8.
Secondary Psychosocial variables associated with exercise capacity - appetite level To examine the effects of the training program with the FAACT questionnaire At week 18 (the end of chemotherapy treatment)
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A